Early feasibility of the Laplace Transcatheter Tricuspid Valve Replacement — Canada

Laplace Outside the US (OUS) Early Feasibility Study (EFS) Canada

This study tries the Laplace transcatheter tricuspid valve replacement to see if it is safe and can be successfully implanted in people aged 60–90 with severe, symptomatic tricuspid regurgitation who remain symptomatic despite optimal medical therapy.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 15 (estimated)
• Ages: 60 Years to 90 Years
• Sex: All
• Sponsor: Laplace Interventional, Inc (industry)
• Locations: 1 site (Toronto, Ontario)
• Trial ID: NCT07171060 on ClinicalTrials.gov

What this trial studies

This is a prospective, single-arm early feasibility study testing the Laplace Transcatheter Tricuspid Valve Replacement (TTVR) system for safety and technical feasibility in patients with severe, symptomatic tricuspid regurgitation. Eligible patients are aged 60–90, remain symptomatic despite at least 30 days of optimal medical therapy, and must have severe/massive/torrential regurgitation confirmed by TTE or TEE using a five-grade classification. Implantation is performed via trans-jugular access and patient selection is confirmed by the local heart team and a central patient selection committee; patients with trans-tricuspid pacing or ICD leads require electrophysiology input. The study requires in-person procedure and scheduled post-procedure follow-up visits at participating centers.

Who should consider this trial

Good fit: Ideal candidates are patients aged 60–90 with severe, massive, or torrential symptomatic tricuspid regurgitation despite at least 30 days of optimal medical therapy who are anatomically suitable for trans-jugular Laplace TTVR and approved by the local heart team.

Not a fit: Patients outside the 60–90 age range, those with less-than-severe tricuspid regurgitation, unsuitable anatomy or vascular access, or other contraindications identified by the heart team are unlikely to benefit from this early feasibility procedure.

Why it matters

Potential benefit: If successful, the Laplace TTVR system could provide a less invasive option to reduce tricuspid regurgitation, relieve symptoms, and improve quality of life for patients not helped by medical therapy.

How similar studies have performed: Transcatheter tricuspid valve replacement is a relatively new approach with limited early feasibility data; small early reports have shown technical promise but large-scale efficacy and safety remain unproven.

Eligibility criteria

Inclusion Criteria:

1. 60 - 90 years of age at the time of the study procedure
2. Symptomatic tricuspid regurgitation despite being adequately treated with optimal medical therapy by the Local Heart Team for at least 30 days prior to the time of study consent.
3. Severe, massive or torrential tricuspid regurgitation determined by qualifying transthoracic echocardiogram (TTE) and/or transesophageal echocardiogram (TEE) using the 5-grade classification.
4. Candidate felt suitable for transcatheter tricuspid valve replacement as determined by the local heart team and confirmed by the patient selection committee. For patients with pre-existing trans-tricuspid pacemaker or ICD leads, the local heart team shall include an electrophysiologist.
5. Anatomically suitable for the Laplace TTVR system including trans-jugular access 6 Subject or legally authorized representative has provided informed consent and agrees to return for all required post-procedure follow-up visits

Exclusion Criteria:

1. Estimated life expectancy of less than 12 months
2. Systolic pulmonary artery pressure \> 65mmHg per TTE.
3. PVR \>5 Wood units
4. Acutely decompensated defined as hypotension with SBP \<90 mmHg, use of hemodynamic support devices or inotropes within the last 30 days
5. Severe COPD dependent on home oxygen or chronic home oxygen use
6. Echocardiographic evidence of severe right ventricular dysfunction
7. Severe aortic, mitral and/or pulmonic valve stenosis and/or regurgitation requiring treatment
8. New or untreated right heart chamber or/and superior vena cava intracardiac mass, thrombus, or vegetation
9. Presence of significant congenital heart disease including but not limited to hemodynamically significant atrial septal defect, RV dysplasia, and arrhythmogenic RV.
10. Untreatable hypersensitivity or contraindication to any of the following: Aspirin, and Clopidogrel or Ticlopidine, Heparin, and Bivalirudin, Warfarin, or DOAC, Nitinol Alloys. Severe renal insufficiency defined as eGFR \<25 mL/min or requiring chronic renal replacement therapy at the time of screening committee review.

12\. Current history (within last 5 years) of illicit drug use. 13. Any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery, within last 30 days. Implant or revision of any rhythm management device (CRT or CRT-D) or implantable cardioverter-defibrillator or leadless pacemaker within 90 days prior to the study procedure 14. Need for emergent, urgent or planned surgery or intervention within 30 days following the study procedure. Planned or scheduled cardiac surgery within next 12 months. 15. Stroke or other major cerebrovascular event within 90-days prior to index procedure 16. Untreated clinically significant coronary artery disease requiring revascularization, recent (within last 30 days) acute coronary syndrome or myocardial infarction. 17. Active or recent GI bleed within 30 days prior to study procedure or patients Contraindicated for oral anticoagulation therapy 18. Bleeding disorders including thrombocytopenia or platelet count \<70,000 mm 3 or thrombocytosis (platelet count \>700,000 /mm 3

* Transfusion dependent chronic anemia with Hb \<9/dL
* Current or planned pregnancy within next 12 months for women of childbearing potential
* Active or recent endocarditis within last 90 days or, sepsis/ other systemic infection requiring oral or intravenous antibiotics within last 30 days
* Prior tricuspid repair or tricuspid replacement or other device that would interfere with successful deployment or functioning of Laplace tricuspid valve.
* Participation in another pre-market investigational device study or investigational drug study for a cardiac related drug
* Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements. Any patient considered to be vulnerable.
* Left ventricular ejection fraction (LVEF) \< 30%
* Deep vein thrombosis or pulmonary embolism within last 6 months
* Child-Pugh C cirrhosis.
* Contraindication or inability to complete TEE

Where this trial is running

Toronto, Ontario

• Sunnybrook Research Institute — Toronto, Ontario, Canada (RECRUITING)

Study contacts

• Study coordinator: Ryan Gladney

Conditions: Tricuspid Regurgitation